Bipolar depression: the role of atypical antipsychotics

References

• Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Genet. Psychiatry 59, 530–537 (2002).
   Google Scholar
• Post RM, Denicoff KD, Leverich GS et al. Morbidity in 258 bipolar out-patients followed for 1 year with daily prospective ratings on the NIMH life chart method. J. Clin. Psychiatry 64, 680–690 (2003).
   Google Scholar
• Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Genet. Psychiatry 60, 261–269 (2003).
   Google Scholar
• Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 17, 491–511 (2003).
   Google Scholar
• Perugi G, Micheli C, Akiskal HS et al. Polarity of the first episode, clinical characteristics, and course of manic depressive illness: a systematic retrospective investigation of 320 bipolar I patients. Compr. Psychiatry 41, 13–18 (2000).
   Google Scholar
• Keller MB, Lavori PW, Coryell W et al. Differential outcome in pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA 255, 3138–3142 (1986).
   Google Scholar
• Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J. Clin. Psychopharmacol. 13, 397–408 (1993).
   Google Scholar
• Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month study of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar disorder. J. Clin. Psychiatry 64, 1013–1024 (2003).
   Google Scholar
• Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Genet. Psychiatry 60, 392–400 (2003).
   Google Scholar
• Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry 60, 79–88 (1999).
   Google Scholar
• Parker G, Parker K. Which antidepressants flick the switch? Aust. NZ J. Psychiatry 37, 464–468 (2003).
   Google Scholar
• Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord. 5, 407–420 (2003).
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry 159(Suppl. 4), 1–50 (2002).
   Google Scholar
• Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 17, 149–173 (2003).
   Google Scholar
• Keck PE Jr, McElroy SL. New approaches in managing bipolar depression. J. Clin. Psychiatry 64(Suppl. 1), 13–18 (2003).
   Google Scholar
• Kasper S. Treatment of depressive symptoms with quetiapine. Expert Rev. Neurotherapeutics 3, 89–95 (2003).
   Google Scholar
• Kasper S, Stamenkovic M, Letmaier M, Schreinzer D. Atypical antipsychotics in mood disorders. Int. Clin. Psychopharmacol. 17(Suppl. 3), S1–S10 (2002).
   Google Scholar
• Lahti RA, Tamminga CA. Effect of amphetamine, alpha-methyl-p-tyrosine and antipsychotic agents on dopamine D2-type receptor occupancy in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 23, 1277–1283 (1999).
   Google Scholar
• Schotte A, Janssen PF, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57–73 (1996).
   Google Scholar
• Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18, 63–101 (1998).
   Google Scholar
• Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 1081–1090 (2003).
   Google Scholar
• Richelson E. Synaptic effects of antidepressants. J. Clin. Psychopharmacol. 16(3 Suppl. 2), 1S–7S (1996).
   Google Scholar
• Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmaology (Berl) 112, 285–292 (1993).
   Google Scholar
• Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression. Arch. Genet. Psychiatry 60, 1079–1088 (2003).
   Google Scholar
• Vieta E, Goikolea JM, Corbella B et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J. Clin. Psychiatry 62, 818–825 (2001).
   Google Scholar
• Calabrese J, Macfadden W, McCoy R, Minkwitz M, Wilson E, Mullen J. Double-blind, placebo-controlled study of quetiapine in bipolar depression. 157th Annual Meeting of the American Psychiatric Association, NY, USA. 1–6th May (2004).
   Google Scholar
• Baldassano CF, Paulsson B, Brecher M. Quetiapine treatment of depressive symptoms in bipolar mania. 157th Annual Meeting of the American Psychiatric Association, 1–6th May, NY, USA (2004) (Abstract NR736).
   Google Scholar
• DelBello MP, Schwiers ML, Rosenberg HL, Stratowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J. Am. Acad. Child. Adolesc. Psychiatry 41, 1216–1223 (2002).
   Google Scholar
• Ghaemi SN, Goldberg JF, Henry CA et al. Quetiapine for rapid-cycling bipolar disorder: a long-term follow-up study. Bipolar Disord. 5(Suppl. 1), 50 (2003) (Abstract p73).
   Google Scholar
• Brown ES, Nejtek VA, Perantie DC, Bobadilla L. Quetiapine in patients with bipolar disorder and cocaine dependence. Bipolar Disord. 4, 406–411 (2002).
   Google Scholar
• Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in out-patients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin. Ther. 23, 1839–1854 (2001).
   Google Scholar
• Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 26, 137–149 (2001).
   Google Scholar
• Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in out-patients with psychosis. J. Clin. Psychiatry 63, 1156–1163 (2002).
   Google Scholar
• Zarate CA Jr, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J. Clin. Psychiatry 61, 185–189 (2000).
   Google Scholar
• Keck PE Jr. New anti-epileptics in the treatment of bipolar disorder. Poster presented at the 154th Annual Meeting of the American Psychiatric Association, May 5–10, New Orleans, LA, USA (2001) (Abstract 34E).
   Google Scholar
• Post RM, Leverich GS, Altshuler LL et al. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord. 5, 310–319 (2003).
   Google Scholar
• Suppes T, McElroy S, Keck P et al. Use of quetiapine in bipolar disorder: a case series with prospective evaluation. Int. Clin. Psychopharmacol. 19, 173–174 (2004).
   Google Scholar
• Becker D, Liver O, Mester R et al. Risperidone, but not olanzapine, decreases bone mineral density in female pre-menopausal schizophrenia patients. J. Clin. Psychiatry 64, 761–766 (2003).
   Google Scholar